Anavex Life Sciences Corp

NASDAQ:AVXLUnited States

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Contact Information

Headquarters

630 5Th Avenue, 20Th FloorNEW YORK, NY, United States 10111

Phone

800-689-3939

Fax

---

Executives

Chairman of the Board, President, Chief Executive Officer, Company Secretary

Christopher Missling

Principal Financial Officer, Treasurer

Sandra Boenisch

Independent Director

Peter Donhauser

Independent Director

Jiong Ma

Independent Director

Athanasios Skarpelos